EMA/388980/2020

European Medicines Agency decision

P/0293/2020

of 12 August 2020

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for guselkumab (Tremfya), (EMEA-001523-PIP05-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0293/2020

of 12 August 2020

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for guselkumab (Tremfya), (EMEA-001523-PIP05-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Janssen-Cilag International N.V. on 15 July 2019 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 26 June 2020, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for guselkumab (Tremfya), solution for injection in pre-filled pen, solution for injection in pre-filled syringe, solution for injection, subcutaneous use, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for guselkumab (Tremfya), solution for injection in pre-filled pen, solution for injection in pre-filled syringe, solution for injection, subcutaneous use, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for guselkumab (Tremfya), solution for injection in pre-filled pen, solution for injection in pre-filled syringe, solution for injection, subcutaneous use, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision covers all conditions, indications, pharmaceutical forms, routes of administration, measures, timelines, waivers and deferrals, as agreed in the decision P/0073/2016 issued on 18 March 2016, including subsequent modifications thereof.

Article 5

This decision is addressed to Janssen-Cilag International N.V., Turnhoutseweg 30, B2340 – Beerse, Belgium.

EMA/PDCO/217785/2020
Amsterdam, 26 June 2020

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-001523-PIP05-19

Scope of the application

Active substance(s):

Guselkumab

Invented name:

Tremfya

Condition(s):

Treatment of Crohn's Disease

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Solution for injection in pre-filled pen

Solution for injection in pre-filled syringe

Solution for injection

Route(s) of administration:

Subcutaneous use

Intravenous use

Name/corporate name of the PIP applicant:

Janssen-Cilag International N.V.

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Janssen-Cilag International N.V. submitted for agreement to the European Medicines Agency on 15 July 2019 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 20 August 2019.

Supplementary information was provided by the applicant on 25 March 2020. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of Crohn's Disease

The waiver applies to:

- the paediatric population from birth to less than 2 years;
- solution for injection in pre-filled pen, solution for injection in pre-filled syringe, solution for injection, subcutaneous use, intravenous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition:

Treatment of Crohn's Disease

2.1.1. Indication(s) targeted by the PIP

Treatment of moderately to severely active Crohn's disease in paediatric subjects from 2 to less than 18 years with, who have had an inadequate response, lost response, or were intolerant to either conventional therapy or biologic therapy

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Solution for injection in pre-filled pen

Solution for injection in pre-filled syringe

Solution for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable
Non-clinical studies	0	Not applicable
Clinical studies	1	Study 1 (CNTO1959CRD3002)

Area	Number of measures	Description
		Open-label induction study in which all patients receive intravenous (IV) guselkumab induction dosing, followed by a randomized, double-blind, 2-arm study of subcutaneous (SC) guselkumab maintenance to assess pharmacokinetics (PK), efficacy, and safety in paediatric subjects from 2 to less than 18 years with moderately to severely active Crohn's disease, who have had an inadequate response, lost response, or were intolerant to either conventional therapy or biologic therapy
Extrapolation, modelling and simulation studies	2	Study 2 Extrapolation/interpolation population PK model Study 3 Extrapolation/interpolation exposure response model
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By October 2026
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of psoriasis

Authorised indication(s):

- Tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy

Authorised pharmaceutical form(s):

Solution for injection in pre-filled syringe

Solution for injection in pre-filled pen

Authorised route(s) of administration:

Subcutaneous use